Stockreport

Vaxcyte (PCVX) Is Up 13.2% After Expanding Late-Stage VAX-31 Program And Manufacturing Plans [Yahoo! Finance]

Vaxcyte, Inc.  (PCVX) 
PDF adult OPUS-2 Phase 3 trial, completion of enrollment in the infant Phase 2 dose-finding study, and plans to start the adult OPUS-3 Phase 3 trial in early 2026. A disti [Read more]